BioPharma Joint Steering Committee Strategic Renewal Dialogue Script

Role: Life Sciences Enterprise Account Strategist leading biopharma governance reviews.

Context

• Enterprise Client: {{pharma_enterprise}}
• Therapeutic Portfolio: {{therapeutic_area}}
• Current Enterprise Scope: {{data_platform_scope}}
• Target Drug Program Milestone: {{pipeline_milestone}}
• Commercialization Bottleneck: {{payer_access_challenge}}
• Proposed Growth Add-on: {{expansion_module}}

Task

Produce a collaborative meeting facilitation script for a Joint Steering Committee (JSC) with {{pharma_enterprise}}, aligning past delivery milestones in {{therapeutic_area}} with upcoming {{pipeline_milestone}} demands to secure expansion into {{expansion_module}}.

Method

1. Establish the meeting purpose around strategic pipeline acceleration rather than vendor service review.
2. Script an opening review recognizing joint achievements across {{data_platform_scope}}.
3. Formulate open questions assessing the risk profile of {{pipeline_milestone}}.
4. Introduce a diagnostic dialogue around overcoming {{payer_access_challenge}} using real-world evidence.
5. Present a structured transition introducing {{expansion_module}} as the logical enabler for future pipeline gates.
6. Script handling for pushback regarding R&D budget allocation or internal IT readiness.
7. Craft a collaborative closing dialogue establishing a 60-day enterprise evaluation scope.

Constraints

• Script MUST accommodate two distinct speakers: Account Director and Client Executive Sponsor.
• MUST NOT frame the conversation as a sales pitch; position it strictly as joint account governance.
• Terminology MUST reflect biopharma R&D lifecycle and clinical development standards.
• Total output script MUST remain under 900 words.

Output format

Provide the complete multi-speaker dialogue script containing:

• Agenda & Executive Opening Narrative (Account Director)
• Joint Value Checkpoint & Milestone Diagnostic (Dialogue between Account Director and Client Sponsor)
• Strategic Expansion Transition & Risk Exploration (Account Director introducing {{expansion_module}})
• Governance Action Items & Renewal Alignment Agreement (Shared closing dialogue)

Self-review

• Does the dialogue establish equal peer footing between the vendor strategist and the biopharma client?
• Is {{payer_access_challenge}} logically solved by incorporating {{expansion_module}}?
• Are stage cues clearly demarcating speaker changes and tone shifts?